Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
FDA labeling for EGRIFTA WR states that tesamorelin is indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy, while also noting that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. For a research comparison article, Tesamorelin gives useful context: it shows that the GHRH analog category is not limited to CJC-1295 and Sermorelin
Regular check-ins with health care professionals can support these efforts
BPC-157 is available in both oral and injectable forms, allowing flexibility in how it is used based on individual needs
Maharjan R, Lim DS, Baik HJ, Park HE, Kim MS, Kim KH, et al
